A phase-2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2022）
Abstract
Further evaluation is needed to establish fexinidazole's minimum effective dosage and risk-benefit relationship. Results suggest potential for effective treatment regimens of <10 days.
MoreTranslated text
Key words
Trypanosoma cruzi,Chagas disease,fexinidazole,neglected tropical diseases
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined